跳至主要内容
临床试验/NCT03201627
NCT03201627Unknown早期 1 期

a Single-center, Prospective, Open, and Non-randomized Case-control Study of Lithium Carbonate Effect on Niemann Disease C1 Type

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2017年7月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
入组人数
18
试验地点
1
主要终点
NPC clinical severity score

研究概览

简要总结

This study is planned to study whether lithium carbonate has protective effect on the brain of Niemann-Pick disease type C1.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
7 Years 至 40 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • aged from 7 years to 40 years
  • onset of neurological symptoms prior to 15 years of age
  • confirmed diagnosis of NPC1 determined by either two NPC1 mutations or one NPC1 mutation with elevated plasma 7-ketocholesterol
  • ability to walk either independently or with assistance
  • Subject or parent/guardian able to communicate with investigator, understand and abide the rules of this clinical trial.
  • parent/guardian able to accompany the subjects to participate in the clinical trial
  • Subject or parent/guardian must provide written informed consent

排除标准

  • One NPC clinical severity scale score reached 5
  • Female in pregnancy or breastfeeding
  • The predicted life span less than 1 year
  • Severe liver insufficiency (defined as hepatic laboratory parameters, AST and/or ALT greater than three-times the upper limit of normal
  • Renal insufficiency, with the serum creatine greater than 1.5 times the upper limit of normal
  • Free with neurological symptoms
  • Take antidiuretic hormone

研究组 & 干预措施

treatment

Experimental

干预措施: Lithium Carbonate (Drug)

结局指标

主要结局

NPC clinical severity score

时间窗: 52 weeks

次要结局

  • 7-ketocholesterol(52 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Huiwen Zhang, MD

Associate Prof.

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

研究点 (1)

Loading locations...

相似试验